Urologix March Stock Price Gain Propelled By BPH Systems, Disposables
This article was originally published in The Gray Sheet
Executive Summary
Increased market penetration and improved reimbursement rates for Urologix, Inc.'s Targis Cooled ThermoTherapy system for treatment of benign prostatic hyperplasia (BPH) translated into a nearly 30% stock price gain in March. The issue advanced $4.17 to close at $18.17 for the month